CD8A and neoplasm: Although these pDC clinical trials have clearly shown that vaccination with pDCs could lead to induction of anti-tumor CD8 T cell immunity [82,85,86] despite their presumed tolerogenic role in tumors in multiple tumors [29,30,74,75,76], how pDCs achieve these opposite function through cross-priming remains poorly understood [87,88].